Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

the write-down of goodwill of $599.4 million recorded in the third quarter of 2008, leaving no goodwill on our books as of December 31, 2008. - As of December 31, 2008, cash, short and long-term investments were $41.4 million and net debt was $535.2 million.

Significant Recent Developments

New Senior Secured Credit Facilities. On March 2, 2009 we announced that we had completed a financing transaction with Wells Fargo Foothill, LLC. The financing includes a delayed draw secured term loan facility of up to $10 million, and a secured revolving credit facility with a borrowing base derived from the value of certain of the Company's finished goods inventory and accounts receivable, providing up to an additional $22.5 million in available credit, subject to certain terms and conditions. Any borrowings outstanding under the term loan and revolving credit facility bear interest ranging from LIBOR + 3.25% to LIBOR +3.75%, with a minimum Base LIBOR Rate of 2.25%. The term loan and the revolving credit facility include certain covenants and restrictions with respect to our operations, require us to maintain certain levels of Adjusted EBITDA and interest coverage ratios, among other terms and conditions, and are secured by the assets of the Company and its Canadian and U.S. subsidiaries. The purpose of the financings is to provide additional liquidity and capital resources for working capital and general corporate purposes.

Financial and Strategic Alternatives Process. During approximately the last eight calendar quarters, our royalty revenue has declined significantly, primarily due to lower than expected royalties derived from sales by our partner Boston Scientific Corporation ("BSC") of TAXUS(R) coronary stent systems. This decline in royalty revenue has significantly impacted our ability to fund our operations and service our debt obligations, and has impacted our liquidity position. During
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... news release is available in German . ... too well: with the naked eye, you can see which ... in the blur of branches through the telephoto lens for ... for researchers who are looking to study proteins, the active ... ETH Zurich,s Institute for Molecular Systems Biology, and her colleagues ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The paradigm ... complex biological systems that can help predict the adverse ... Dr. Sergey Stepaniants, Head of Computational Biology at the ... biology tools to ensure high-quality genomics when used as ... be applied to complex data sets to identify key ...
(Date:5/16/2013)... The Stirling Ultracold Model SU780U ... Athens, OH, USA, won the Outstanding New Product Award ... for Biological and Environmental Repositories (ISBER) at their annual ... product annually, recognizes the company’s development and introduction of ... The award was presented to Global Cooling’s CEO Neill ...
Breaking Biology Technology:Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2
... in Jefferson, Wis., would be converted for ethanol production ... a new company in Jefferson Junction, Wis. , ,Jefferson ... of Jefferson and invest more than $200 million ... into a multi-use facility including an ethanol plant, a ...
... of Midwest life sciences, one of the most difficult issues ... along a pathway to commercial launch of products and some ... Midwest VC groups in 16 states with combined capital of ... Mid-America Healthcare Investors Network . , ,Aside from the ...
... MailFoundry offers new anti-spam solutions , ... "human intelligence" based anti-spam solutions, announced two new ... and 8100. They are priced at $6,999 and ... limits or restrictions. , ,All MailFoundry anti-spam appliances ...
Cached Biology Technology:The challenge of financing today's Midwest life science companies 2The challenge of financing today's Midwest life science companies 3The challenge of financing today's Midwest life science companies 4The challenge of financing today's Midwest life science companies 5The challenge of financing today's Midwest life science companies 6Tech Digest: MailFoundry; API Software 2
(Date:5/16/2013)... a commitment to the support of underrepresented minority ... Foundation has announced the inaugural AGA Investing in ... by the National Institute of Diabetes and Digestive ... underrepresented minority students to further their research careers ... establishing this new award, AGA demonstrates its commitment ...
(Date:5/16/2013)... gene involved in neurodegenerative disease also plays a critical ... , In a study of the common fruit ... the clock responsible for sleeping and waking on a ... fruit fly,s sleep-wake cycle is disturbed, making waking up ... , The discovery is particularly interesting because mutations in ...
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2Gene involved in neurodegeneration keeps clock running 2
... are still debating this question, a new study, ... supports the view that the first egalitarian ... years before the French Revolution, Marx, and Lenin. ... and their origin had dramatic implications for humanity. ...
... thought, a study in mice has found that inactivating ... actually increase energy expenditure and help lower diet-induced obesity. ... JBC, might lead to some new roads in ... need to continually "burn fat" in order to maintain ...
... to their work site, they sequentially attach to and ... known as the extracellular matrix. Now, in research to ... , scientists at the Howard Hughes Medical Institute and ... regulate and power this movement from the inside - ...
Cached Biology News:Egalitarian revolution in the Pleistocene? 2Egalitarian revolution in the Pleistocene? 3Egalitarian revolution in the Pleistocene? 4Making metabolism more inefficient can reduce obesity 2Scientists identify a molecule that coordinates the movement of cells 2
... Glycine Transporter 2, Neuronal (GLYT2). The antiserum ... the central nervous system. The staining pattern ... described using in situ hybridization with probes ... been described for glycinergic neurons. Preabsorption of ...
... cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide White solid. ... A potent inhibitor of MMP-2 that acts ... = 1.7 μM). Purity: ≥98% by ... Unstable in solution, reconstitute just prior to ...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Biology Products: